To examine longitudinal trends in trimodality therapy (TMT) use among patients with inflammatory breast cancer (IBC) and compare breast cancer-specific survival (BCSS) and overall survival (OS) between IBC and non-IBC, both overall and across tumor subtypes.
Key Findings:
IBC patients had poorer BCSS and OS compared to non-IBC patients, with significant demographic disparities impacting treatment outcomes.
TMT use among IBC patients was evaluated, showing no significant de-escalation in treatment over time.
Demographic differences were noted, with IBC patients more likely to be non-Hispanic White and single, and have lower median income, which may influence treatment access and outcomes.
Interpretation:
The study highlights the persistent disparities in outcomes between IBC and non-IBC, emphasizing the need for continued adherence to TMT for IBC due to its aggressive nature and the implications for patient survival.
Limitations:
The study is based on registry data, which may have inherent biases.
Potential confounding factors, such as socioeconomic status and access to care, were not accounted for in the analysis.
Conclusion:
Despite advancements in treatment, IBC remains associated with worse survival outcomes compared to non-IBC, underscoring the importance of aggressive treatment strategies.
by José P. Leone, Julieta Leone, Pietro De Placido, Faina Nakhlis, Ilana Schlam, Kelly A. Hirko, Aditi Hazra, Elizabeth Troll, Jennifer R. Bellon, Carlos T. Vallejo, Nancy U. Lin, Sara M. Tolaney, Filipa Lynce
